Skip to content

Ibutilide

    Brands

    DEA Class; Rx

    Common Brand Names; Corvert

    • Antidysrhythmics, III

    Class III antiarrhythmic agent; used IV for rapid conversion of atrial fibrillation or atrial flutter to normal sinus rhythm.

    Indicated for the rapid cardioversion of recent onset atrial fibrillation or atrial flutter.

    Hypersensitivity to drug or excipients

    • Headache (4%)
    • Bradycardia (2%)
    • HTN (2%)
    • Hypotension (2%)
    • Palpitations (2%)
    • QTc interval prolongation (<2%)
    • Nausea (>2%)
    • Heart failure
    • Erythematous bollous lesions
    • Nodal arrythmia
    • Renal failure
    • Ventricular tachycardia
    • Syncope
    • Heart block
    • Torsades de pointes
    • Potentially lethal arrhythmias: sustained polymorphic V-Tach (Torsades de Pointes), AV block

    Administer in a setting of continuous ECG monitoring and by personnel trained in treating arrhythmias such as polymorphic ventricular tachycardia

    Monitor for heart block

    The potential for proarrhythmia may increase with administration of this drug to patients who are being treated with drugs that prolong the QT interval, such as phenothiazines, tricyclic antidepressants, tetracyclic antidepressants, and certain antihistamine drugs (H1 receptor antagonists)

    This drug should not be administered to a pregnant woman unless clinical benefit outweighs potential risk to fetus

    The excretion of ibutilide into breast milk has not been studied; accordingly, breastfeeding should be discouraged during therapy with this drug

    Adults

    2 mg IV (infused over at least 20 minutes).

    Elderly

    2 mg IV (infused over at least 20 minutes).

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Ibutilide

    injectable solution

    • 0.1mg/mL